The presence of gastric spirochaetal organisms was first documented over a century ago. Though repeatedly reported in the medical literature, it was felt that these spiral bacteria were merely contaminants and the reports were generally ignored by the medical community. On 22 October 1982, at a meeting of the Royal Australian College of Physicians, successful culture of these 'Campylobacterlike organisms' from gastric biopsy specimens was reported for the first time. Moreover, it was shown that their presence was associated with gastritis and, possibly, with peptic ulceration. The subsequent discovery of the pivotal role of Helicobacter pylori in a wide range of conditions has revolutionised our understanding of gastroduodenal diseases. Improvements in diagnostic and therapeutic options, combined with the gradual acceptance of the aetiological role of an infective agent in peptic disease, have led to a remarkable change in the management of gastroduodenal conditions in the past decade.
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European consensus report on the management of H. pylori infection and duodenum were described in patients with heartburn and upper abdominal pain 3 . During the eighteenth and nineteenth centuries, understanding of the function of the upper gastrointestinal tract gradually increased with the description of the digestive properties of gastric secretions 4 and hydrochloric acid in the stomach 5 . In 1825, William Beaumont, an American army physician, reported his famous series of in vivo gastric function experiments in a patient who developed a gastro-cutaneous fistula following a gunshot wound 6 . The symptomatology of peptic ulceration was first described in detail in 1857 7 . At this time, gastric ulceration was a common autopsy finding, especially in females, while duodenal ulceration was rarely reported.
With the ability to clinically diagnose upper gastrointestinal conditions, gastric surgery developed during the second half of the nineteenth century. Theodor Billroth described gastroduodenostomy and gastrojejunostomy in 1881 8 . In the same year, the first potentially usable endoscope was reported 9 . In 1897, using bismuth subnitrate as a contrast material, the ability to diagnose peptic ulceration radiographically was reported 10 . Duodenal ulceration, rarely reported in the nineteenth century, began to increase dramatically in prevalence in young and middle-age males and, by 1900, was more common than gastric ulceration.
The treatment of peptic ulceration changed after the pronouncement of the dictum 'no acid, no ulcer' in 1910 by the Croatian, Karl Schwarz 11 . Antacids were recommended in the treatment of peptic ulcer in 1915 12 . In the modern era, the first substance to show promise in peptic ulcer disease was stilboestrol in 1960, followed by carbenoxolone in 1962 13 . In 1966, the gastric histamine receptor was described 14 followed shortly by the first Hj receptor antagonist 15 . The advent of this class of drugs dramatically improved the management of peptic ulceration, allowing symptom control and a reduction in the rate of complications. Shortly after, the presence of a potassium-stimulated adenosine triphosphatase (H + /K + -ATPase) pump was demonstrated 16 . Six years later, the first commercially available proton pump inhibitor was reported 17 . While these drugs were effective inhibitors of acid secretion with the ability to heal ulcers, relapse of ulceration after cessation of treatment was frequent resulting in the need for long-term maintenance treatment.
Gastric spiral bacteria
The presence of gastric spiral bacteria was first reported in 1893 18 . Bizzozero, an Italian pathologist, described spiral bacteria in the canine stomach. In 1896, Salomon reported similar findings in the stomachs of cats and mice 19 . Spiral bacteria were demonstrated, for the first time, in the human stomach in 1906 20 . This initial report concerned patients with gastric carcinoma. Nine years later, spiral micro-organisms in the stomachs of patients with gastric and duodenal ulceration were reported 21 . It was felt, however, that these organisms were contaminants from the oral cavity.
At this time, the presence of urease activity in the human stomach was documented 22 . It was thought that this urease activity originated in gastric mucosal cells and was not associated with the presence of bacteria.
In 1938, spirochaetes were found in 43% of 242 autopsy stomachs using a haematoxylin and eosin stain 23 . The following year, spirochaetes were reported in 37% of 35 gastric resection specimens from patients with gastric ulcer or carcinoma 24 . In 1954, however, a study of 1000 gastric biopsy specimens failed to confirm these findings and interest in gastric bacteria lapsed 25 . In 1950, Fitzgerald and Murphy studied urease in the resected stomachs of patients with gastric ulceration (Fig. 1) . They suggested that urease activity protected the gastric mucosa by mediating a reaction between urea and hydrogen ions, thus neutralising gastric acid via the production of ammonia 26 . In addition, they administered urea to ulcer patients and demonstrated that this resulted in a neutralising of gastric acid. Nine years later, it was demonstrated that gastric urease activity diminished after administration of tetracycline 27 . The bacterial source of gastric urease was confirmed in 1968, when the absence of urease activity was demonstrated in the stomachs of germ-free animals 28 . In 1975, bacteria were reported in association with gastritis in 80% of gastric resection specimens from patients with gastric ulceration 29 . Moreover, persistence of gastritis and the bacteria was demonstrated 
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after carbenoxolone-mediated ulcer healing 30 . Interest in the role of gastric bacteria in the pathogenesis of 'peptic' conditions was rekindled in 1979 when spiral bacteria were described on the luminal surface of epithelial cells of gastric ulcer patients 31 . Three years later, the beneficial effect of bismuth on duodenal mucosa in patients with duodenal ulceration was demonstrated 32 .
The modern era began in 1981 when a second-year medical internist, Barry Marshall, began a clinical research project with Robin Warren, a histopathologist, in the Royal Perth Hospital, Western Australia (Fig. 2) . Warren had stained gastric biopsy specimens with the Warthin-Starry stain and noted the presence of mucosal bacteria. Marshall treated an elderly Russian patient with gastritis and gastric bacteria with tetracycline and noted clearance of the infection and improvement of the gastritis 33 . Subsequent attempts to culture these bacilli were unsuccessful until April 1982. During the Easter weekend, the plates were unintentionally incubated for 5 days and colonies were visible 34 . The 35 . These 'Campylobacter-hke organisms' were called Campylobacter pyloridis, since they were micro-aerobic, curved, Gramnegative bacteria and resembled other campylobacters both morphologically and in guanine/cytosine DNA content 36 . The presence of multiple flagellae on these bacteria, differentiating them from other Campylobacters, was also noted. For grammatical reasons, the name was changed to Campylobacter pylori in 1987 37 . Subsequently, it was shown that C. pylori did not belong to the genus Campylobacter and a new genus name was suggested in 1989 38 -39 . 'Helicobacter' reflects the two morphological appearances of the organism, helical in vivo but often rodlike in vitro (bakter, a staff).
The association with peptic ulceration, and possibly with gastric adenocarcinoma, was initially suggested by Marshall et a/ 36 ' 40 . Another group also described these bacteria in 1984 421 and the association between C. pyloridis and gastric urease activity was demonstrated shortly afterwards 42 . The acute effects of the infection were illustrated after deliberate ingestion of a suspension of the organisms 43 . The Australian group, having noted the historical usage of bismuth in peptic diseases, also demonstrated the inhibitory effect of bismuth salts on the organism 44 . Reliable diagnostic techniques which facilitated epidemiological and interventional studies, such as serology 45 , the rapid urease test 46 , the [ 13 C]-and [
14 C]-urea breath tests 47 ' 48 soon became available. The initial reports of an association between an infective organism and gastroduodenal disease were greeted with some scepticism by the gastroenterology community. This was perhaps understandable given their recently acquired ability to treat such conditions effectively with acid reducing agents. A group of specialists with an interest in the infection, the European H. pylori Study Group, was formed in Copenhagen in 1987 and this was followed by an exponential increase into the study of the role of the bacteria in gastroduodenal diseases. The group were also responsible for increasing awareness of the importance of the infection in the gastroenterology community.
Clinical studies -clarification of role of H. pylori
The first long-term clinical trial of treatment aimed at eradicating 'C. pylori" in patients with duodenal ulceration, based in the Meath/Adelaide Hospitals, Dublin was reported in 1987 (Fig. 3) 49 . This study revealed that eradication of the bacterium was followed by a significant reduction in ulcer relapse rates and suggested that eradication permanently cured duodenal ulcer disease. This was followed by multiple studies which confirmed this finding 50 " 54 . A similar decrease in gastric ulcer relapse rates was also subsequently reported 55 -56 . The relationship between the organism and gastric adenocarcinoma and MALT (gastric mucosa-associated lymphoid tissue) lymphoma was reported in 1991 57 " 60 . Subsequent studies assessed the role of the organism in gastro-oesophageal reflux disease 61 , patients receiving long-term acid suppressing medication 62 . In 1997, it was 'strongly recommended' by a European consensus panel that patients with H. pylori infection and peptic ulcer, low grade mucosaassociated lymphoid tissue lymphoma, severe macroscopic or microscopic gastritis or recently resected early gastric cancer should receive a proton pump inhibitor-based triple therapy to eradicate the infection 69 . In addition, it was felt that treatment aimed at eradication was 'advisable' in H. pylori positive individuals with non-ulcer dyspepsia, a family history of gastric cancer, gastroesophageal reflux disease necessitating long-term proton pump inhibitor therapy, planned or ongoing non-steroidal anti-inflammatory drug indigestion, and following gastric surgery for peptic ulcer disease or gastric cancer.
Conclusion
The discovery of H. pylori and the gradual realisation of its importance in upper gastrointestinal diseases represents one of the most important developments in medicine in the past century. Physicians are now able to cure hitherto chronic diseases with short, safe antibiotic-based treatments. It has also given rise to the potential to prevent a variety of gastroduodenal conditions. Whether this will be done by communitybased screening programmes or vaccination should become clear in the next decade. Churchill Livingstone, 1857
